In CD34+ cells from MPN patients, treatment with pegylated IFNα-2a causes an increase in apoptosis and phosphorylation/activation of p38 mitogen-activated protein kinase (MAPK), which leads to increase p53 transcription [40]. The gene discussed is CD34; the disease is myeloproliferative disorder.